Income Insurance Ltd Makes New $793,000 Investment in Merck & Co., Inc. $MRK

Income Insurance Ltd purchased a new position in Merck & Co., Inc. (NYSE:MRK) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 7,530 shares of the company’s stock, valued at approximately $793,000.

A number of other hedge funds have also recently added to or reduced their stakes in MRK. Brighton Jones LLC lifted its stake in shares of Merck & Co., Inc. by 29.5% in the 4th quarter. Brighton Jones LLC now owns 38,278 shares of the company’s stock valued at $3,808,000 after purchasing an additional 8,710 shares in the last quarter. Sivia Capital Partners LLC lifted its stake in shares of Merck & Co., Inc. by 52.2% in the 2nd quarter. Sivia Capital Partners LLC now owns 11,494 shares of the company’s stock valued at $910,000 after purchasing an additional 3,941 shares in the last quarter. Diversify Advisory Services LLC lifted its stake in shares of Merck & Co., Inc. by 94.1% in the 2nd quarter. Diversify Advisory Services LLC now owns 32,256 shares of the company’s stock valued at $2,590,000 after purchasing an additional 15,636 shares in the last quarter. Diversify Wealth Management LLC lifted its stake in shares of Merck & Co., Inc. by 22.2% in the 2nd quarter. Diversify Wealth Management LLC now owns 38,031 shares of the company’s stock valued at $3,054,000 after purchasing an additional 6,897 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Merck & Co., Inc. by 111.7% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 681,128 shares of the company’s stock valued at $53,918,000 after purchasing an additional 359,356 shares in the last quarter. 76.07% of the stock is owned by institutional investors and hedge funds.

Merck & Co., Inc. Stock Performance

Shares of NYSE:MRK opened at $111.26 on Friday. The company has a market cap of $274.78 billion, a P/E ratio of 31.34, a PEG ratio of 2.51 and a beta of 0.18. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.30 and a current ratio of 1.30. Merck & Co., Inc. has a one year low of $73.31 and a one year high of $125.14. The business’s 50-day simple moving average is $117.07 and its 200 day simple moving average is $108.31.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, beating the consensus estimate of ($1.47) by $0.19. The business had revenue of $16.29 billion for the quarter, compared to the consensus estimate of $15.85 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The company’s revenue was up 4.9% on a year-over-year basis. During the same period last year, the business posted $2.22 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, sell-side analysts forecast that Merck & Co., Inc. will post 5.16 earnings per share for the current fiscal year.

Insider Activity

In other Merck & Co., Inc. news, EVP Jennifer Zachary sold 121,573 shares of Merck & Co., Inc. stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $119.15, for a total transaction of $14,485,422.95. Following the sale, the executive vice president directly owned 68,916 shares in the company, valued at $8,211,341.40. The trade was a 63.82% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CMO Chirfi Guindo sold 10,000 shares of Merck & Co., Inc. stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $118.41, for a total value of $1,184,100.00. Following the sale, the chief marketing officer owned 70,615 shares in the company, valued at $8,361,522.15. This represents a 12.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.17% of the company’s stock.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck published a landmark Science paper on a new large-scale biocatalytic synthesis method for its investigational oral PCSK9 inhibitor, enlicitide decanoate. The work supports manufacturing scalability for a potential future cardiovascular drug and underscores progress in Merck’s pipeline. Article Title
• Positive Sentiment: Merck also became the sole testing provider for Genetix Biotherapeutics’ FDA-approved gene therapies under a five-year agreement, strengthening its BioReliance services business and adding a recurring commercialization-related revenue stream. Article Title
• Neutral Sentiment: Analyst commentary highlighted Merck as a well-prepared dividend stock despite its upcoming patent cliff, suggesting the market is still weighing long-term earnings durability rather than reacting to a single catalyst. Article Title
• Negative Sentiment: Merck is heading toward a July 27 trial over Gardasil safety claims after the vaccine reached an $8.9 billion sales peak. The litigation risk could weigh on sentiment around one of Merck’s key growth franchises, even though the company continues to defend the product’s safety record. Article Title

Analyst Ratings Changes

Several equities analysts have recently weighed in on MRK shares. Wall Street Zen raised Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research note on Saturday, March 28th. Citigroup assumed coverage on Merck & Co., Inc. in a research note on Wednesday. They issued a “neutral” rating and a $125.00 price objective on the stock. Zacks Research upgraded Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 17th. Deutsche Bank Aktiengesellschaft upgraded Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $150.00 target price on the stock in a report on Friday, February 13th. Finally, UBS Group raised their target price on Merck & Co., Inc. from $130.00 to $145.00 and gave the company a “buy” rating in a report on Monday, April 13th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $128.18.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.